{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:06:35Z","timestamp":1791993995135,"version":"4.4.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.bioorg.2024.107314","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T00:24:09Z","timestamp":1712190249000},"page":"107314","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Bioisosteric replacement strategy leads to novel DNA gyrase B inhibitors with improved potencies and properties"],"prefix":"10.1016","volume":"147","author":[{"given":"Wenjie","family":"Xue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueping","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maosheng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huali","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10325","key":"10.1016\/j.bioorg.2024.107314_b0005","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0140-6736(22)00087-3","article-title":"The overlooked pandemic of antimicrobial resistance","volume":"399","author":"Laxminarayan","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.bioorg.2024.107314_b0010","unstructured":"J. O'Neill, Antimicrobial Resistance : Tackling a crisis for the health and wealth of nations, Review on Antimicrobial Resistance (2014)."},{"key":"10.1016\/j.bioorg.2024.107314_b0015","unstructured":"G.H.T. Helen W. Boucher1, John S. Bradley3,4, John E. Edwards5,6,7, David Gilbert8, Louis B. Rice9,10, Michael Scheld11, Brad Spellberg5,6,7,, J. Bartlett12, Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America, Clinical Infectious Diseases 48(1) (2009) p.1-12."},{"issue":"8","key":"10.1016\/j.bioorg.2024.107314_b0020","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1086\/533452","article-title":"Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE","volume":"197","author":"Rice","year":"2008","journal-title":"J. Infect. Dis."},{"issue":"7722","key":"10.1016\/j.bioorg.2024.107314_b0025","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41586-018-0483-6","article-title":"Optimized arylomycins are a new class of gram-negative antibiotics","volume":"561","author":"Smith","year":"2018","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bioorg.2024.107314_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13756-017-0291-z","article-title":"Economic burden of nosocomial infections caused by vancomycin-resistant enterococci","volume":"7","author":"Puchter","year":"2018","journal-title":"Antimicrob. Resist. Infect. Control"},{"issue":"10","key":"10.1016\/j.bioorg.2024.107314_b0035","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/s41570-021-00313-1","article-title":"Towards the sustainable discovery and development of new antibiotics","volume":"5","author":"Miethke","year":"2021","journal-title":"Nat. Rev. Chem."},{"key":"10.1016\/j.bioorg.2024.107314_b0040","doi-asserted-by":"crossref","unstructured":"R.T. A, P.K. B, A.D. A, N.S. C, S.C. A, Antibiotics: past, present, and future, Drug Discovery Targeting Drug-Resistant Bacteria (2020) 1-8.","DOI":"10.1016\/B978-0-12-818480-6.00001-1"},{"key":"10.1016\/j.bioorg.2024.107314_b0045","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bioorg.2015.07.004","article-title":"Dual targeting DNA gyrase B (GyrB) and topoisomerse IV (ParE) inhibitors: a review","volume":"62","author":"Azam","year":"2015","journal-title":"Bioorg. Chem."},{"issue":"12","key":"10.1016\/j.bioorg.2024.107314_b0050","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1007\/s00018-010-0299-5","article-title":"In front of and behind the replication fork: bacterial type IIA topoisomerases","volume":"67","author":"Sissi","year":"2010","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bioorg.2024.107314_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112326","article-title":"Recent advances in DNA gyrase-targeted antimicrobial agents","volume":"199","author":"Dighe","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2024.107314_b0060","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1021\/acsinfecdis.0c00025","article-title":"Advancement of GyrB inhibitors for treatment of infections caused by Mycobacterium tuberculosis and non-tuberculous mycobacteria","volume":"6","author":"Stokes","year":"2020","journal-title":"ACS Infect. Dis."},{"issue":"21","key":"10.1016\/j.bioorg.2024.107314_b0065","doi-asserted-by":"crossref","first-page":"8792","DOI":"10.1021\/jm500563g","article-title":"Second-generation antibacterial benzimidazole ureas: discovery of a preclinical candidate with reduced metabolic liability","volume":"57","author":"Grillot","year":"2014","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2024.107314_b0070","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1021\/acsmedchemlett.5b00368","article-title":"Discovery of Pyrazolopyridones as a novel class of gyrase B inhibitors using structure guided design","volume":"7","author":"Cross","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"issue":"12","key":"10.1016\/j.bioorg.2024.107314_b0075","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1021\/acsmedchemlett.0c00416","article-title":"Exploring the chemical space of benzothiazole-based DNA gyrase B inhibitors","volume":"11","author":"Skok","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"issue":"17","key":"10.1016\/j.bioorg.2024.107314_b0080","doi-asserted-by":"crossref","first-page":"5349","DOI":"10.1016\/j.bmcl.2010.02.060","article-title":"Design, synthesis, and biological evaluation of a novel series of quercetin diacylglucosides as potent anti-MRSA and anti-VRE agents","volume":"20","author":"Hossion","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"1\u20136","key":"10.1016\/j.bioorg.2024.107314_b0085","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/13543776.2019.1575362","article-title":"ATP-competitive DNA gyrase and topoisomerase \u2163 inhibitors as antibacterial agents","volume":"29","author":"Durcik","year":"2019","journal-title":"Expert Opin. Ther. Pat."},{"issue":"12","key":"10.1016\/j.bioorg.2024.107314_b0090","article-title":"Single-ascending-dose study in healthy subjects to assess the safety, tolerability, Pharmacokinetics, and Pharmacodynamics of DS-2969b, a novel GyrB inhibitor, the journal of clinical Pharmacology: official journal of the American College of Clinical","volume":"58","author":"Giorgio","year":"2018","journal-title":"Pharmacology"},{"issue":"2","key":"10.1016\/j.bioorg.2024.107314_b0095","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11020371","article-title":"DNA gyrase as a Target for quinolones","volume":"11","author":"Spencer","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.bioorg.2024.107314_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.115026","article-title":"Current scenario of quinolone hybrids with potential antibacterial activity against ESKAPE pathogens","volume":"247","author":"Gao","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107314_b0105","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1007\/s00044-013-0518-3","article-title":"In-silico design, synthesis and evaluation of novel DNA-gyrase B inhibitors","volume":"22","author":"Patel","year":"2013","journal-title":"Med. Chem. Res."},{"issue":"22","key":"10.1016\/j.bioorg.2024.107314_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115776","article-title":"Lead optimization of 8-(methylamino)-2-oxo-1,2-dihydroquinolines as bacterial type II topoisomerase inhibitors","volume":"28","author":"Ushiyama","year":"2020","journal-title":"Bioorg. Med. Chem."},{"issue":"22","key":"10.1016\/j.bioorg.2024.107314_b0115","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1002\/jcc.26693","article-title":"Novel 6-hydroxyquinolinone derivatives: design, synthesis, antimicrobial evaluation, in silico study and toxicity profiling","volume":"42","author":"Saleh","year":"2021","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bioorg.2024.107314_b0120","unstructured":"C. Zhou, Z. Li, X. Qian, J. Cheng, P. Maienfisch, Novel Acaricidal Silico-Containing Pyrazolyl Acrylonitrile Derivatives Identified through Rational Carbon-Silicon Bioisosteric Replacement Strategy."},{"issue":"36","key":"10.1016\/j.bioorg.2024.107314_b0125","doi-asserted-by":"crossref","first-page":"11123","DOI":"10.1021\/acs.jafc.2c00654","article-title":"Bioisosteric-replacement-driven Lead optimization of tyclopyrazoflor","volume":"70","author":"Chen","year":"2022","journal-title":"J. Agric. Food Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107314_b0130","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1080\/14756366.2022.2084088","article-title":"Discovery of N-quinazolinone-4-hydroxy-2-quinolone-3-carboxamides as DNA gyrase B-targeted antibacterial agents","volume":"37","author":"Xue","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107314_b0135","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ejmech.2016.03.079","article-title":"New N-phenyl-4,5-dibromopyrrolamides and N-phenylindolamides as ATPase inhibitors of DNA gyrase","volume":"117","author":"Zidar","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107314_b0140","unstructured":"C. Institute, N. Pa, M.A. Wikler, M. Wikler, Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically: Approved standard Clsi (Nccls) 26 (2006) M7-A7."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107314_b0145","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1124\/jpet.109.153320","article-title":"1,4-Diamino-2,3-dicyano-1,4-bis(methylthio)butadiene (U0126) enhances the cytotoxicity of combretastatin A4 independently of mitogen-activated protein kinase kinase","volume":"330","author":"Quan","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"21","key":"10.1016\/j.bioorg.2024.107314_b0150","doi-asserted-by":"crossref","first-page":"8503","DOI":"10.1021\/acs.jmedchem.5b00961","article-title":"Discovery of azaindole ureas as a novel class of bacterial gyrase B inhibitors","volume":"58","author":"Zhang","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107314_b0155","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ejmech.2018.11.036","article-title":"Optimization of a 1,3,4-oxadiazole series for inhibition of Ca2+\/calmodulin-stimulated activity of adenylyl cyclases 1 and 8 for the treatment of chronic pain","volume":"162","author":"Kaur","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107314_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.112022","article-title":"N-thiadiazole-4-hydroxy-2-quinolone-3-carboxamides bearing heteroaromatic rings as novel antibacterial agents: design, synthesis, biological evaluation and target identification","volume":"188","author":"Xue","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2024.107314_b0165","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1021\/acs.jmedchem.2c01905","article-title":"New dual inhibitors of bacterial Topoisomerases with broad-spectrum antibacterial activity and in vivo efficacy against vancomycin-intermediate Staphylococcus aureus","volume":"66","author":"Durcik","year":"2023","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2024.107314_b0170","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1021\/ci100436p","article-title":"FRED pose prediction and virtual screening Accuracy","volume":"51","author":"McGann","year":"2011","journal-title":"J. Chem. Inf. Model."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824002190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824002190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T08:53:31Z","timestamp":1715676811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206824002190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":34,"alternative-id":["S0045206824002190"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107314","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bioisosteric replacement strategy leads to novel DNA gyrase B inhibitors with improved potencies and properties","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107314","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107314"}}